Document:

Exhibit 10.15

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

AMENDMENT #5 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

UC Case No: ***

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

    	 

    	 

    

 

 

AMENDMENT #5 TO:

EXCLUSIVE LICENSE FOR

***

 

UC Case No: ***

 

 

 

Effective March 1, 2004 (the “EFFECTIVE
DATE OF AMENDMENT #5”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111
Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology Licensing, at the University
of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620 (“REGENTS”) and KINEMED, INC., a
Delaware corporation having a principal place of business at EmeryStation North, 5980 Horton Street, Suite 470, Emeryville, CA
94608-2012 (“LICENSEE”), agree to amend ,that certain Agreement between REGENTS and LICENSEE which bears an’
effective date of February 16, 2001 (as amended previously through Amendments #1, #2, #3, and #4, said Amendments bearing effective
dates of June 15, 2002, October 15, 2002, March 25, 2003, and November 6, 2003 respectively), as follows:

 

ARTICLE 1.1 (p) (BACKGROUND) add the
following:

 

1.1p) ***

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #5	Page 2	Confidential

    	 

    

 

 

 

 

ARTICLE 2.1(k) (DEFINITIONS) substitute
the following:

 

(k) All of Regents’
United States patent applications filed under U.C. Case Numbers .: *** as described in Article 1.1 (c) through (p) above, and;

 

ARTICLE 5.1(b) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(b) As of the EFFECTIVE
DATE OF AMENDMENT #5, REGENTS acknowledges the LICENSEE has fully paid to REGENTS all stock and cash license and amendment fees
that were due to REGENTS under the original Agreement and under Amendments #1, #2, #3 and #4 thereto.

 

As consideration for the
addition of REGENTS’ case *** by way of this fifth amendment to the Agreement, LICENSEE shall also pay to’ REGENTS
a non-creditable, non-refundable fee of *** on or before *** and shall, within *** days after the final execution of this amendment
#5 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS employee(s) a total
of *** shares of common stock in KineMed, Inc., in accordance with the Shareholder’s Agreements between REGENTS and LICENSEE
attached hereto as Exhibit A.

 

ARTICLE 5.1(c) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(c) For any of the following U.C. Case
Numbers: *** as described in Article 2.1(k) and in Article 1.1 (c) through (p) above, if the corresponding patent application(s)
have not resulted in at least one VALID CLAIM, then for each such U.C. Case Number, LICENSEE shall be entitled to a *** to REGENTS
pursuant to Article 6.1.

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #5	Page 3	Confidential

    	 

    

 

 

 

All remaining terms and conditions of the
Agreement (as amended) remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement in duplicate originals by their duly authorized officers or representatives.

 

	THE REGENTS OF THE	 	KINEMED, INC.
	UNIVERSITY OF CALIFORNIA	 	 
	 	 	 	 
	By	/s/ Carol Mimura	 	By	/s/ James E. Burden
	 	Carol Mimura, Ph.D.	 	 	James E. Burden
	 	Director	 	 	COO & Secretary
	 	Office of Technology Licensing	 	 	 
	 	 	 	 	 
	Date	April 15, 2004	 	Date	April 14, 2004

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #5	Page 4	ConfidentialExhibit 10.16

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 

 

AMENDMENT #6 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

UC Case Nos: ***

 

 

 

    	 

    	 

    

 

AMENDMENT #6 TO:

EXCLUSIVE LICENSE FOR 

***

 

Effective September
22, 2005 (the “EFFECTIVE DATE OF AMENDMENT #6”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation,
whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology
Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620 (“REGENTS”)
and KINEMED, INC., a Delaware corporation having a principal place of business at EmeryStation North, 5980 Horton Street, Suite
400, Emeryville, CA 94608-2012 (“LICENSEE”), agree to amend that certain Agreement between REGENTS and LICENSEE which
bears an effective date of February 16, 2001 (as amended previously through Amendments #1, #2, #3, #4, and #5 said Amendments bearing
effective dates of June 15, 2002, October 15, 2002, March 25, 2003, November 6, 2003, and March 1, 2004, respectively), as follows:

 

ARTICLE 1.1 (q) (BACKGROUND) add the
following:

 

1.1 q)
***, and;

 

1.1 r)
***.

 

ARTICLE 2.1(k) (DEFINITIONS) substitute
the following:

 

(k) All of Regents'
United States patent applications filed under U.C. Case Numbers .: ***, as described in Article 1.1 (c) through (r) above, and;

 

ARTICLE 4.1(a) (SUBLICENSES) substitute
the following:

 

(a)    LICENSEE will have
the right to sublicense to third party sublicensees (“SUBLICENSEES”) the rights granted in Article 3.1, provided that
LICENSEE has current exclusive rights under this AGREEMENT, and provided that LICENSEE pays to REGENTS within *** days following
execution of any sublicense agreement the following percentage of the SUBLICENSE FEES:

 

		(i)	*** of SUBLICENSE FEES up to *** of SUBLICENSE FEES;

 

		(ii)	*** of the SUBLICENSE FEES in excess of *** up to *** of SUBLICENSE FEES;

 

		(iii)	*** of the SUBLICENSE FEES in excess of *** up to *** of SUBLICENSE FEES;

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #6 KINEMED	Page 2 of 3	 

    	 

    

 

		(iv)	*** of the SUBLICENSE FEES in excess of *** up to *** of SUBLICENSE FEES; and,

 

		(v)	*** of the SUBLICENSE FEES in excess of *** of SUBLICENSE FEES.

 

ARTICLE 5.1(b) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(b) As of the EFFECTIVE
DATE OF AMENDMENT #6, REGENTS acknowledges the LICENSEE has fully paid to REGENTS all stock and cash license and amendment fees
that were due to REGENTS under the original Agreement and under Amendments #1, #2, #3, #4, and #5 thereto.

 

As consideration for
the addition of REGENTS' cases *** and *** by way of this sixth amendment to the Agreement, LICENSEE shall also pay to REGENTS
a non-creditable, non-refundable fee of *** on or before *** days after the final execution of this amendment #6 to the Agreement,
and shall cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS employee(s) a total of *** shares
of common stock in KineMed, Inc., in accordance with the Stock Purchase Agreement between REGENTS and LICENSEE attached hereto
as Exhibit A.

 

ARTICLE 5.1(e) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(c) For any of the
following U.C. Case Numbers: ***, as described in Article 2.1(k) and in Article 1.1 (c) through (r) above, if the corresponding
patent application(s) have not resulted at least one VALID CLAIM, then for each such U.C. Case Number, LICENSEE shall be entitled
to *** REGENTS pursuant to Article 6.1.

 

All remaining terms
and conditions of the Agreement (as amended) remain in full force and effect.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or representatives.

 

	THE REGENTS OF THE	 	KINEMED, INC.	 
	UNIVERSITY OF CALIFORNIA	 	 	 	 
	 	 	 	 	 	 
	By	/s/ Veronica Lanier	 	By	/s/ James E. Burden	 
	 	Veronica Lanier	 	 	James E. Burden	 
	 	Acting Director	 	 	COO & Secretary	 
	 	 	 	 	Office of Technology Licensing	 
	 	 	 	 	 	 
	Date:  September 22, 2005	 	Date:  September 22, 2005	 

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #6 KINEMED	Page 3 of 3Exhibit 10.17

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 

 

AMENDMENT #7 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

U.C. Agreement No.: ***

 

UC Case Nos: ***

 

    	 

    	 

    

 

AMENDMENT #7 TO:

EXCLUSIVE LICENSE FOR 

***

 

U.C. Case Nos: ***

 

Effective April 11,
2011 (the “EFFECTIVE DATE OF AMENDMENT #7”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation,
whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of
Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347
(“REGENTS”) and KINEMED, INC., a Delaware corporation having a principal place of business at EmeryStation North,
5980 Horton Street, Suite 400, Emeryville, CA 94608-2012 (“LICENSEE”), agree to amend that certain Agreement between
REGENTS and LICENSEE which bears an effective date of February 16, 2001 (as amended previously through Amendments #1,
#2, #3, #4, #5 and #6 said Amendments bearing effective dates of June 15, 2002, October 15, 2002, March 25, 2003, November
6, 2003, March 1, 2004, and September 22, 2005 respectively), as follows:

 

ARTICLE 4.1(a) (SUBLICENSES) substitute
the following:

 

(a) LICENSEE will
have the right to sublicense to third party sublicensees (“SUBLICENSEES”) the rights granted in Article 3.1, provided
that LICENSEE has current exclusive rights under this AGREEMENT, and provided that LICENSEE pays to REGENTS within ***
days following execution of any sublicense agreement the following percentage of the SUBLICENSE FEES:

 

		(i)	*** of SUBLICENSE FEES up to *** of SUBLICENSE FEES;

 

		(ii)	*** of the SUBLICENSE FEES in excess of *** up to *** of SUBLICENSE FEES;

 

		(iii)	*** of the SUBLICENSE FEES in excess of *** up to *** of SUBLICENSE FEES; and,

 

		(iv)	*** of the SUBLICENSE FEES in excess of *** of SUBLICENSE FEES.

 

For the avoidance of doubt the
value of SUBLICCENSE FEES for the percentage calculation in (i) to (iv) shall be a cumulative value that will be a sum based
on all SUBLICENSES.

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #7 KINEMED	Page 2 of 3	 

    	 

    

 

All remaining terms
and conditions of the Agreement (as amended) remain in full force and effect.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or
representatives.

 

	THE REGENTS OF THE	KINEMED, INC.
	UNIVERSITY OF CALIFORNIA	 

 

	By:	/s/ Irvin J. Mettler, Ph.D.	 	By:	/s/David M. Fineman	 
	 	Irvin J. Mettler, Ph.D.	 	 	David M. Fineman	 
	 	Associate Director	 	 	President and CEO	 
	 	Office of Technology Licensing	 	 	 	 

 

	Date:	April 15, 2011	 	Date:	April 12, 2011	 

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #7 KINEMED	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]